Explorative Metabolism from Clinical or Toxicology Samples

Pivotal toxicology studies and early clinical trials provide material, which can be used to obtain important information about human and animal metabolites and their potential impact on the safety profile of the investigational drug.

Even without a radiolabel, it is possible to screen plasma or excreta samples for unknown metabolites. WuXi DMPK metabolism experts in the US and China can provide more value for your study, including:

  • Screening for metabolites in clinical and preclinical samples
  • Full structure elucidation and relative abundance of key metabolites
  • Use of radio-calibrants for preliminary quantitative assessment
  • Synthesis of metabolite reference standards
  • Development of validated methods for quantification of metabolites
  • Toxicological assessment and activity testing of metabolites